Array-818-202 for Non-small Cell Lung Cancer

What is the Purpose of this Study?

We are doing this study to learn about the safety and effectiveness of the study drugs (Encorafenib and Binimetinib) in patients.
What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in this Study?

Adults 19 years or older with NSCLC with a gene called BRAFV600E that has mutated.

Age Group
Adults
Participating Institutions

What is Involved?

If you choose to join this study, you will:

-Be in the study up to 2 years

-Take study drugs daily

-Give blood samples

-Possible give a small lung tissue sample

-Continue with your regular care

Study Details

Full Title
PHAROS: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF-V600E-mutant Non-small Cell Lung Cancer
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00102193

NCT:
NCT03915951
ClinicalTrials.gov
View on ClinicalTrials.gov